(INNS)
UPANOVIMAB(INND)
UPANOVIMAB(INNC)
IMMUNOGLOBULIN G1-KAPPA, ANTI-[SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE (S) GLYCOPROTEIN, RECEPTOR BINDING DOMAIN (RBD)], MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN (1-451) [VH MUSMUS/HOMSAP (MUS MUSCULUS IGHV5-9-4*01 (89.8%) -(IGHD) - IGHJ3*01 (91.7%) A128>S (121)/HOMO SAPIENS IGHV3-21*01 (85.7%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) - HOMO SAPIENS IGHG1*01, G1M17,1, G1V14 CH2 A1.3, A1.2 (CH1 K120 (218) (122-219), HINGE 1-15 (220- 234), CH2 L1.3>A (238), L1.2>A (239) (235-344), CH3 D12 (360), L14 (362) (345-449), CHS (450-451)) (122- 451)], (224-218')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'- 218') [V-KAPPA MUSMUS/HOMSAP...; PROPOSED INN: LIST 125, RECOMMENDED INN: LIST 87(WHO)
UPANOVIMABUM(INN)